MiR-199b-5p targets HER2 in breast cancer cells

Trastuzumab Produces Therapeutic Actions by Upregulating miR-26a and miR-30b in Breast Cancer Cells

(2012) Takehiro Ichikawa et al.   PLoS One

Modulation of MicroRNA-194 and Cell Migration by HER2-Targeting Trastuzumab in Breast Cancer

(2012) Xiao-Feng Le et al.   PLoS One

ErbB2 down-regulates microRNA-205 in breast cancer

(2011) Ryohei Adachi et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Identification of New MicroRNAs in Paired Normal and Tumor Breast Tissue Suggests a Dual Role for the ERBB2/Her2 Gene

(2011) H. Persson et al.   CANCER RESEARCH

Mechanisms of resistance to anti-human epidermal growth factor receptor 2 agents in breast cancer

(2010) Toru Mukohara   CANCER SCIENCE

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

(2010) S. Flamant et al.   HAEMATOLOGICA

Resistance to ErbB2 Tyrosine Kinase Inhibitors in Breast Cancer Is Mediated by Calcium-Dependent Activation of RelA

(2010) W. Xia et al.   MOLECULAR CANCER THERAPEUTICS

Decreased expression of microRNA-199b increases protein levels of SET (protein phosphatase 2A inhibitor) in human choriocarcinoma

(2009) Angel Chao et al.   CANCER LETTERS

Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL

(2009) L. Liu et al.   CANCER RESEARCH

Causes and consequences of microRNA dysregulation in cancer

(2009) Carlo M. Croce   NATURE REVIEWS GENETICS

MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma

(2009) Livia Garzia et al.   PLoS One

The roles of microRNA in cancer and apoptosis

(2008) Niamh Lynam-Lennon et al.   BIOLOGICAL REVIEWS

Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235

(2008) P. J.A. Eichhorn et al.   CANCER RESEARCH

MicroRNA-21 targets tumor suppressor genes in invasion and metastasis

(2008) Shuomin Zhu et al.   CELL RESEARCH

EXEL-7647 Inhibits Mutant Forms of ErbB2 Associated with Lapatinib Resistance and Neoplastic Transformation

(2008) T. Trowe et al.   CLINICAL CANCER RESEARCH

Lapatinib Resistance in HCT116 Cells Is Mediated by Elevated MCL-1 Expression and Decreased BAK Activation and Not by ERBB Receptor Kinase Mutation

(2008) A. P. Martin et al.   MOLECULAR PHARMACOLOGY

FDA Drug Approval Summary: Lapatinib in Combination with Capecitabine for Previously Treated Metastatic Breast Cancer That Overexpresses HER-2

(2008) Q. Ryan et al.   ONCOLOGIST